We discovered that patients with lower mRNA expression of ZMYND11 exhibited an increased risk of postoperative biochemical relapse, tumor progression to metastasis, and a shorter overall survival time42,45,47 (Fig. 1g, h and Supplementary Fig. 1e, f). Here, ZMYND11 is linked to neoplasm.